Cprx stock forecast.

Dec 1, 2023 · Catalyst Pharmaceuticals last released its quarterly earnings data on November 8th, 2023. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, hitting the consensus estimate of ($0.26). The business earned $102.69 million during the quarter, compared to the consensus estimate of $100.17 million. See the latest Catalyst Pharmaceuticals Inc stock price (CPRX:XNAS), related news, valuation, dividends and more to help you make your investing decisions.According to the issued ratings of 5 analysts in the last year, the consensus rating for Altimmune stock is Moderate Buy based on the current 1 hold rating and 4 buy ratings for ALT. The average twelve-month price prediction for Altimmune is $13.80 with a high price target of $25.00 and a low price target of $6.00.We've seen plenty of personal finance tools designed to help you track what you're spending, but web site PocketSmith is an impressive new web-based personal finance tool with an emphasis on forecasting your financial future. We've seen ple...

Find the latest Catalyst Pharmaceuticals, Inc. CPRX analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports. Date …Shares of CPRX were one of the market’s most successful stock stories in 2022. That’s because they delivered investors a year-to-date gain of over 136% (through Dec. 16). And while it’s true ...23 sty 2023 ... PRICE. %CHG. VOL%CHG. "My Stock Lists is a premium feature and available ... CPRX stock has led the IBD 50 list of elite growth stocks for weeks.

Read more to see why CPRX stock is a Strong Buy. Skip to content. Explore Alpha Picks; Subscribe to Premium; ... the company forecasts a non-GAAP full-year 2023 net income of between $195 million ...

AVIR Stock 12 Months Forecast. $4.00. (40.35% Upside) Based on 1 Wall Street analysts offering 12 month price targets for Atea Pharmaceuticals in the last 3 months. The average price target is $4.00 with a high forecast of $4.00 and a low forecast of $4.00. The average price target represents a 40.35% change from the last price of $2.85.Catalyst Pharmaceuticals, Inc. (CPRX) : Free Stock Analysis Report. ... The median home sale price will fall 1.7% next year after eking out an anticipated 0.2% gain in 2023, according to the forecast.The U.S. National Weather Service (NWS) is a part of the National Oceanic and Atmospheric Administration (NOAA). Many people rely on the National Weather Service’s forecasts in order to better anticipate what the weather will be like so the...Nov 24, 2023 · Based on short-term price targets offered by five analysts, the average price target for Catalyst Pharmaceutical comes to $23.30. The forecasts range from a low of $15.50 to a high of $27.00. The ...

For Catalyst Pharmaceuticals stock forecast for 2023, 1 predictions are offered for each month of 2023 with average Catalyst Pharmaceuticals stock forecast of $13.76, a high forecast of $13.76, and a low forecast of $13.76. The average Catalyst Pharmaceuticals stock forecast 2023 represents a 0.34% increase from the last price of $13.710000038147.

7 brokerages have issued 12-month price targets for Cross Country Healthcare's shares. Their CCRN share price targets range from $21.00 to $40.00. On average, they anticipate the company's share price to reach $27.50 in the next year. This suggests a possible upside of 34.7% from the stock's current price.

DHT Stock 12 Months Forecast. Based on 4 Wall Street analysts offering 12 month price targets for DHT Holdings in the last 3 months. The average price target is $12.93 with a high forecast of $15.00 and a low forecast of $11.00. The average price target represents a 16.59% change from the last price of $11.09.CPRX Stock 12 Months Forecast. $23.30. (81.32% Upside) Based on 5 Wall Street analysts offering 12 month price targets for Catalyst Pharma in the last 3 months. The average price target is $23.30 with a high forecast of $27.00 and a low forecast of $15.50. The average price target represents a 81.32% change from the last price of $12.85. View Catalyst Pharmaceuticals, Inc CPRX investment & stock information. Get the latest Catalyst Pharmaceuticals, Inc CPRX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.For the current quarter, Catalyst is expected to post earnings of $0.21 per share, indicating a change of +133.3% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over ...Catalyst Pharmaceutical (CPRX) is one such stock that our proprietary system currently recommends. The company not only has a favorable Growth Score, but also carries a top Zacks Rank. Studies ...

Catalyst Pharmaceuticals last released its quarterly earnings data on November 8th, 2023. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, hitting the consensus estimate of ($0.26). The business earned $102.69 million during the quarter, compared to the consensus estimate of $100.17 million.REAL Stock 12 Months Forecast. $4.25. (101.90% Upside) Based on 3 Wall Street analysts offering 12 month price targets for RealReal in the last 3 months. The average price target is $4.25 with a high forecast of $6.00 and a low forecast of $3.25. The average price target represents a 101.90% change from the last price of $2.11.Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements. Catalyst is expected to post earnings of $0.22 ...26 sty 2023 ... So, is this biotech on the road to desolation, or is the crash of its stock just an overreaction by panicky markets? Expand. NASDAQ: CPRX.NVIDIA Corporation Common Stock. $435.70 -0.93 -0.21%. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers ...

Catalyst (CPRX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.6 mar 2023 ... Catalyst Pharmaceuticals Inc. Common Stock, CPRX stock forecast, stock analysis, stock rating, stock news, share price, company information, ...

See the latest Catalyst Pharmaceuticals Inc stock price (CPRX:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Their TEVA share price targets range from $10.00 to $14.00. On average, they predict the company's stock price to reach $12.40 in the next year. This suggests a possible upside of 26.3% from the stock's current price. View analysts price targets for TEVA or view top-rated stocks among Wall Street analysts.About the Catalyst Pharmaceuticals, Inc. stock forecast. As of 2023 November 26, Sunday current price of CPRX stock is 14.060$ and our data indicates that the asset price has been in a downtrend for the past 1 year (or since its inception).The highest forecast stands at $28.00, while the lowest forecast is $14.00. Overall, the analyst rating consensus for ImmunoGen is a Strong Buy, based on the assessments of 8 Wall Street analysts. ... CPRX Stock Performance: Revenue and Net Income Show Mixed Results, ...Catalyst Pharmaceuticals Inc (CPRX) Stock Price & News - Google Finance Markets Home CPRX • NASDAQ Catalyst Pharmaceuticals Inc Follow Share $14.30 Nov 30, 3:15:15 PM GMT-5 · USD · NASDAQ ·...Find the latest Kiora Pharmaceuticals, Inc. (KPRX) stock quote, history, news and other vital information to help you with your stock trading and investing.Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Catalyst Pharmaceuticals Inc. 12.79. Delayed Data. As of Oct 13. +0.075 / +0.59%. Today’s Change. 11.09. Today ||| 52-Week …

The highest forecast stands at $28.00, while the lowest forecast is $14.00. Overall, the analyst rating consensus for ImmunoGen is a Strong Buy, based on the assessments of 8 Wall Street analysts. ... CPRX Stock Performance: Revenue and Net Income Show Mixed Results, ...

8 brokers have issued 1-year price objectives for RealReal's stock. Their REAL share price targets range from $1.85 to $6.00. On average, they predict the company's stock price to reach $3.45 in the next twelve months. This suggests a possible upside of 55.4% from the stock's current price. View analysts price targets for REAL or view top-rated ...

13 sie 2023 ... The average analyst price target for CPRX stock is $22.40 per share. Here are some additional things to consider when evaluating CPRX stock ...Amryt Pharma plc (NASDAQ:AMYT) posted its quarterly earnings results on Thursday, November, 5th. The company reported ($0.07) EPS for the quarter, topping analysts' consensus estimates of ($0.73) by $0.66. The business earned $49.33 million during the quarter. Amryt Pharma had a negative net margin of 8.19% and a positive …Stock Price Forecast. The 1 analysts offering 12-month price forecasts for Inpixon have a median target of 586,488.00, with a high estimate of 586,488.00 and a low estimate of 586,488.00. The ...Great weather can motivate you to get out of the house, while inclement weather can make you feel lethargic. When the weather’s great we want to be outside enjoying it. For the best regional weather forecasts check out AccuWeather.Analyst Talks 30 A Share. Tesla ( TSLA) investors already lost more than $700 billion on the stock in a year. How much more can this S&P 500 stock drop? Plenty. Shares of the electric-auto maker ...The current average CPRX price target, as estimated by these analysts, is $19.38. The predictions for the future CPRX stock price range from a low of $15.50 to a high of …Stock Price Forecast. The 1 analysts offering 12-month price forecasts for Inpixon have a median target of 586,488.00, with a high estimate of 586,488.00 and a low estimate of 586,488.00. The ...1. Catalyst Pharmaceuticals. Catalyst Pharmaceuticals ( CPRX 1.44%) is crushing Tesla stock because it's in the process of cornering a rare disease market that'll be worth hundreds of millions of ...Find the latest Amylyx Pharmaceuticals, Inc. (AMLX) stock quote, history, news and other vital information to help you with your stock trading and investing.The latest Catalyst Pharmaceutical Partners stock prices, stock quotes, news, and CPRX history to help you invest and trade smarter. ... The 12 analysts offering price forecasts for Catalyst ...

With stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin.Jan 23, 2023 · For the current quarter, Catalyst is expected to post earnings of $0.20 per share, indicating a change of +122.2% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over ... Stock Price Forecast. The 10 analysts offering 12-month price forecasts for Capri Holdings Ltd have a median target of 57.00, with a high estimate of 57.00 and a low estimate of 55.00. The median ...26 sty 2023 ... So, is this biotech on the road to desolation, or is the crash of its stock just an overreaction by panicky markets? Expand. NASDAQ: CPRX.Instagram:https://instagram. russeell 2000sunrun newsstock symbol aiwhy is insurance going up Find the latest Compugen Ltd. (CGEN) stock quote, history, news and other vital information to help you with your stock trading and investing. otcmkts rdbbfex dividends calendar Dec 1, 2023 · Catalyst Pharmaceuticals (CPRX) is a biopharmaceutical company that develops and commercializes therapies for rare diseases. The company's stock price, news, and analysis are based on its market cap, P/E ratio, dividend yield, and earnings growth. The consensus rating is Buy, with a price target of $24.75, an upside of 95.8%. todays top gainers finance.yahoo.com - October 19 at 8:13 AM. Patrick J. McEnany, Chairman and CEO of Catalyst Pharmaceuticals, Receives Prestigious 2023 Lifetime Achievement Award from BioFlorida. finance.yahoo.com - October 16 at 8:46 AM. Those who invested in Catalyst Pharmaceuticals (NASDAQ:CPRX) three years ago are up 291%.The stock is not trading at a cheap price-to-sales ratio, but the company's growth rate and growth potential make it a worthy high-risk growth stock to consider. Two stocks worth considering now